Congratulations Professor Alexander Rösch and his team at the Department of Dermatology at the University Hospital Essen for their recent clinical trial publication. The study “Efficacy of cold atmospheric plasma versus diclofenac 3% gel in patients with actinic keratoses: a prospective,  randomized, and rater-blinded study (ACTICAP)” can be found here: https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.16735

Their clinical trial began in 2017 and its purpose was to test the efficacy of our medical device, the Adtec SteriPlas on actinic keratoses patients in comparison to those treated with Diclofenac 3% gel. The clinical efficacy of this modality is comparable to that of Diclofenac gel. However, unlike Diclofenac, cold atmospheric plasma showed no major side effects. Thus, this modality might be especially well-suited for patients who require nontoxic treatment options, particularly immunocompromised patients and those with extensive field cancerization. This continues to be one of our strongest and most favoured characteristics of the Adtec SteriPlas: no side effects.

We encourage you to read the clinical trial publication and welcome any questions that you have.

#actinickeratoses #actinickeratosis #skin #dermatology #coldplasma #kaltesplasma #clinicaltrial #sideeffects